The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
Open accessThe DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Abstract
Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may induce signaling in tumor cells that contributes to their therapeutic activity. In this study, we show that daratumumab (DARA), a therapeutic human CD38 mAb with a broad-spectrum killing activity, is able to induce programmed cell death (PCD) of CD38+ multiple myeloma tumor cell lines when cross-linked in vitro by secondary Abs or via an FcγR. By comparing DARA efficacy in a syngeneic in vivo tumor model using FcRγ-chain knockout or NOTAM mice carrying a signaling-inactive FcRγ-chain, we found that the inhibitory FcγRIIb as well as activating FcγRs induce DARA cross-linking–mediated PCD. In conclusion, our in vitro and in vivo data show that FcγR-mediated cross-linking of DARA induces PCD of CD38-expressing multiple myeloma tumor cells, which potentially contributes to the depth of response observed in DARA-treated patients and the drug’s multifaceted mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219 · cited 1×
“The homotypic aggregation–related caspase-independent and -dependent PCD was also shown for SAR650984, a chimeric CD38 Ab (40, 41), in the absence of secondary cross-linking.”
BackgroundRetractedKyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssière, J. L., Petit, P. X., & Kroemer, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1661 · Cited by 1,166
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 1×
“Approval was based on two phase II studies of DARA monotherapy (16 mg/kg) in heavily treated patients (2, 3).”
Methodde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationMössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
FcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 1×
“Approval was based on two phase II studies of DARA monotherapy (16 mg/kg) in heavily treated patients (2, 3).”
MethodApoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Cited by
Items 201–300 of 314
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
Tekinalp, A., Gedük, A., Akdeniz, A., Demirsoy, E. T., Gürsoy, V., Ak, M. A., Bağcı, M., Seçilmiş, S., Karadağ, F. K., Uysal, A., et al. (2023) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2023.2023.0029 · Cited by 9
Mehl, J., Akhoundova, D., Bacher, U., Jeker, B., Agocs, G. R., Ruefer, A., Soltermann, S., Soekler, M., Winkler, A., Daskalakis, M., et al. (2024) · Cancers · doi:10.3390/cancers16101854 · Cited by 9
Jiang, H., Li, L., Guo, M., Li, M., Wu, H., Chen, X., Gao, M., Xu, Q., Mi, J. D., Cui, C., et al. (2024) · Hematology · doi:10.1080/16078454.2024.2399430 · Cited by 9
Cook, G., Corso, A., Streetly, M. J., Менделеева, Л. П., Ptushkin, V. V., Chan, E. S., Ukropec, J., Iraqi, W., Al-Akabawi, A., Pei, H., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-020-00137-x · Cited by 9
Mustafa, N. B., Azaman, M. I. B., Ng, G. G. K., & Chng, W. J. (2022) · Biomolecules · doi:10.3390/biom12091261 · Cited by 9
The safety of daratumumab for the treatment of multiple myeloma
Cejalvo, M. J., Ribas, P., & de la Rubia, J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1328053 · Cited by 9
Antibody therapies for multiple myeloma
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., & Terpos, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1717464 · Cited by 9
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab
Qing, M., Zhou, T., Perova, T., Abraham, Y., Sweeney, C. M., Krevvata, M., Zhang, X., Qi, M., Gao, G., Kim, T. M., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-023-05603-w · Cited by 8
Youssef, M., Arnesen, C., Arledge, C., Langley, C., Sylvester, D., Sikora, J., Marques, M. B., Zheng, X. L., & Williams, L. A. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.12.019 · Cited by 8
Tauseef, A., Zafar, M., Silberstein, P. T., Nahas, J., Frederickson, T., Abodunrin, F., Abbas, A., Arshad, W., Lateef, N., Rangoonwala, H. I., et al. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1987_21 · Cited by 8
Li, S., Chen, D., Yang, Y., Guo, H., Liu, D., Sun, N., Bai, X., Wang, K., Li, T., Li, G., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1398508 · Cited by 8
Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma
Lamarthée, B., de Vassoigne, F., Malard, F., Stocker, N., Boussen, I., Mediavilla, C., Tang, R., Fava, F., Garderet, L., Marjanovic, Z., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1444411 · Cited by 8
Lamb, Y. N. (2020) · Drugs · doi:10.1007/s40265-020-01385-x · Cited by 8
Menon, T., Kataria, S., Adhikari, R., Khan, H., Khalid, M. Z., Saeeduddin, M. O., Taj, S., Rehman, U., Tekin, A., & Singh, R. (2021) · Cureus · doi:10.7759/cureus.15098 · Cited by 8
A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021
Ding, H., Zhang, X., Gang, D., He, X., & Jiang, S. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-1962 · Cited by 8
Suzuki, K., Min, C., Kım, K., Lee, J., Shibayama, H., Ko, P., Huang, S., Li, S., Ding, B., Khurana, M., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03204-9 · Cited by 8
Dimopoulos, M. A., Cavo, M., Mateos, M., Facon, T. T. F., Heeg, B. M. S., van Beekhuizen, S., Gebregergish, S. B., Nair, S. C., Pisini, M., Lam, A., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1682571 · Cited by 7
Immunotherapeutic and their immunological aspects: Current treatment strategies and agents
Jain, M., Mishra, A., Singh, M. K., Shyam, H., Kumar, S., Shankar, P., & Singh, S. (2022) · National Journal of Maxillofacial Surgery · doi:10.4103/njms.njms_62_22 · Cited by 7
A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma
Candelaria, P. V., Nava, M., Daniels‐Wells, T. R., & Penichet, M. L. (2023) · Cancers · doi:10.3390/cancers15184533 · Cited by 7
Chen, W., Cai, Z., Chim, C. S., Chng, W. J., Du, J., Fu, C., Gao, W., Hanamura, I., Hou, J. M., Huang, J., et al. (2025) · Clinical Hematology International · doi:10.46989/001c.141401 · Cited by 6
Zayad, A., Magee, G., Mansour, R. A., Chang, M., Ahmed, N., Mushtaq, M. U., Paul, B. A., Green, K. M., Davis, J. A., Skikne, B., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.017 · Cited by 6
Advancements and future trends of immunotherapy in light-chain amyloidosis
Mahadevia, H. J., Ponvilawan, B., Sharma, P., Al‐Obaidi, A., Qasim, H., Koyi, J., Anwer, F., & Raza, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103917 · Cited by 6
Crusoé, E. D. Q., Pimenta, F. C. F., Maiolino, Â., de Castro, N. S., Pei, H., Trufelli, D. C., Fernandez, M., & Herriot, L. B. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.07.005 · Cited by 6
Current and prospective antibody-based therapies in multiple myeloma
Bryer, E. J., DeStefano, C. B., & Kazandjian, D. G. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.11.002 · Cited by 6
Jing, H., Li, Y., Qi, J., Qiu, L., Fu, C., Li, J., Yang, M., Qi, M., Fan, N., Ji, J., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04951-3 · Cited by 6
An, G., Ge, Z., Jing, H., Liu, J., Yang, G., Feng, R., Xu, Z., Qi, M., Wang, J., Song, J., et al. (2024) · Blood Science · doi:10.1097/bs9.0000000000000193 · Cited by 6
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
Cooke, R. E., Koldej, R. M., & Ritchie, D. (2019) · Journal of Oncology · doi:10.1155/2019/2186494 · Cited by 6
McCall, D. C., Catueno, S., Ramakrishnan, R., Tewari, P., Sheikh, I. N., Gibson, A., Núnêz, C., Garcia, M. B., & Cuglievan, B. (2025) · Acta Haematologica · doi:10.1159/000546249 · Cited by 5
Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma
Wang, P., & Jin, S. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i29.7091 · Cited by 5
Krohn, S., Boje, A. S., Gehlert, C. L., Lutz, S., Darzentas, N., Knecht, H., Herrmann, D., Brüggemann, M., Scheidig, A. J., Weisel, K. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908093 · Cited by 5
Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
Hughes, M., & Lentzsch, S. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s325859 · Cited by 5
Choudhry, P., Kasap, C., Patiño-Escobar, B., Gugliemini, O., Geng, H., Sarin, V., Kang, A. S., Kishishita, A., Rampersaud, S., Sarah, L., et al. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100025 · Cited by 5
Klein, C. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-876-3 · Cited by 5
Smith, M. R. (1939) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.26523 · Cited by 5
Díaz-Tejedor, A., Rodríguez‐Ubreva, J., Ciudad, L., Lorenzo-Mohamed, M., González-Rodríguez, M., Castellanos, B., Sotolongo-Ravelo, J., San‐Segundo, L., Corchete, L. A., González-Méndez, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094718 · Cited by 4
Foster, L. H., Anderson, L. D., Chung, A., Chaulagain, C. P., Pettijohn, E. M., Cowan, A. J., Costello, C. L., Larson, S., Sborov, D. W., Shain, K. H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01355-0 · Cited by 4
Horenstein, A. L., Frerichs, K. A., Faini, A. C., van de Donk, N. W. C. J., & Malavasi, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769281 · Cited by 4
de Moraes, F. C. A., Sano, V. K. T., Lôbo, A. D. O. M., Kelly, F. A., Morbach, V., Pasqualotto, E., & Burbano, R. M. R. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040360 · Cited by 4
Fu, W., Bang, S., Huang, H., Kım, K., Li, W., An, G., Lee, J., Cai, Z., Jin, J., Wang, Y., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06303-3 · Cited by 4
Maouche, N., Srinivasan, A., Leary, H., Collings, F., Tseu, B., Vallance, G. D., Ramasamy, K., & Kothari, J. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211067780 · Cited by 4
He, J., Berringer, H., Heeg, B. M. S., Ruan, H., Kampfenkel, T., Dwarakanathan, H. R., Johnston, S. S., Mendes, J., Lam, A., Bathija, S., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02226-x · Cited by 4
Alegre, A. M., de la Rubia, J., Sureda, A. M., Rodríguez, C. E., Suárez, A., Blanchard, M. J., Bargay, J., Rodríguez‐Otero, P., Insunza, A., Palomera, L., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000380 · Cited by 4
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
Paul, B. A., Atrash, S., Bhutani, M., Voorhees, P. M., Hamadeh, I. S., & Usmani, S. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1795829 · Cited by 4
In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancerPreprint
Deng, J., Peng, D. H., Fenyö, D., Yuan, H., Lopez, A., Levin, D. S., Meynardie, M., Quinteros, M., Ranieri, M., Sahu, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.18.537350 · Cited by 4
Bahlis, N. J., Zonder, J. A., Karlin, L., Plesner, T., París, L., Wróbel, T., Hungria, V., Besemer, B., Crusoé, E., Silkjær, T., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2561117 · Cited by 3
Chander, A., Zaim, S. R., Dillon, M. A., Genge, P. C., Moss, N., McGrath, P. I., Kopp, M. S., Lee, K. J., Kuan, E. L., Reading, J., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100087 · Cited by 3
Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
Shibayama, H., Matsumoto, M., Kosugi, H., Shibayama, K., Yamazaki, H., & Iida, S. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02985-9 · Cited by 3
Fu, X.-H., Guan, R.-Y., Huang, Z., Li, Y., Lu, G., Mou, W.-W., & Du, J. (2023) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666230619093300 · Cited by 3
Response to daratumumab-retreatment in patients with multiple myeloma
Souren, L., Ihorst, G., Greil, C., Engelhardt, M. M., & Wäsch, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05991-7 · Cited by 3
Chari, A., Munder, M., Weisel, K. C., Jenner, M. W., Bygrave, C., Petrucci, M. T., Boccadoro, M., Cavo, M., van de Donk, N. W. C. J., Turgut, M., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-020-01601-w · Cited by 3
Li, X., Dosne, A., Pérez‐Ruixo, C., & Ruixo, J. J. P. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01232-8 · Cited by 3
Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance
Yang, J., Yu, Y., Wang, Z., Li, Q.-Q., Ding, N., Leng, X., Cai, J., Zhang, M., Wang, J., Zhou, Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116435 · Cited by 3
Rodríguez‐Otero, P., Voorhees, P. M., Boccadoro, M., Laubach, J. P., Einsele, H., Sborov, D. W., Dimopoulos, M. A., Broijl, A., Mina, R., Spencer, A. G., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.007 · Cited by 2
Daratumumab for CD20 − CD38 + Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
Hong, Z., Hong, Z., Ma, Y., Yin, Q., Liu, M., Huang, W., Zhou, K., Li, D., Li, T., & Zheng, M. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70875 · Cited by 2
DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
Рыжко, В. В., & Канаева, М. Л. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-14-94-102 · Cited by 2
Rola daratumumabu w leczeniu chorych na nawrotowego i opornego szpiczaka plazmocytowego
Salomon‐Perzyński, A., & Jamroziak, K. (2018) · Hematologia · doi:10.5603/hem.2017.0037 · Cited by 2
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_48 · Cited by 2
Xie, D., & Zhang, P.-F. (2025) · BMJ Open · doi:10.1136/bmjopen-2023-076914 · Cited by 2
Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab
Janmaat, M. L., van de Donk, N. W. C. J., van Bueren, J. J. L., Ahmadi, T., Sasser, A. K., Jansson, R. K., Lokhorst, H. M., & Parren, P. W. H. I. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch7 · Cited by 2
Self-citationYu, T., Qiao, C., Lv, M., & Tang, L. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0524-8 · Cited by 2
Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma
Wilmoth, J., Colson, K., Dubin, F., & Kellam, C. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.706-712 · Cited by 2
Hungria, V., Moura, F. L., Costa, A., Ribeiro, E. F. O., Soares, P., Lima, J. S., Ricci, L. A., Arrais-Rodrigues, C., Nucci, F. M., Lima, M. D. M., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06365-3 · Cited by 1
Doshi, A., Filho, J. T. D. S., Grimshaw, A. A., Giri, S., & Costa, L. J. (2025) · British Journal of Haematology · doi:10.1111/bjh.70199 · Cited by 1
Affinity Peptides With pH Sensitivity for the Enrichment of CD38 + Cells
Rusch, G., Meyer, M., Irfan, I. M., Huber, C., Burclaff, J., Magness, S. T., Menegatti, S., & Daniele, M. A.-A. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.70109 · Cited by 1
Liu, Y., Zhang, Y., Yang, W., Du, H., Sun, S., Li, Z., & Zong, D. (2025) · Pharmaceuticals · doi:10.3390/ph19010018 · Cited by 1
Hu, B., Fang, D. H., Jiang, L., Li, T., Chen, K., Cao, J., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1744165 · Cited by 1
Bahlis, N. J., Facon, T. T. F., San-Miguel, J., Usmani, S. Z., Dimopoulos, M. A., Moreau, P., Zweegman, S., Perrot, A., Manier, S., Chari, A., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019323 · Cited by 1
Gao, J., Pei, Y., Wei, L., Yang, B., & Yang, H. U. I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1844062 · Cited by 1
Cross Fire: Daratumumab-Based Therapies Are Standard of Care in Newly Diagnosed Multiple Myeloma
Korde, N., & Usmani, S. Z. (2021) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2021.07.001 · Cited by 1
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
Galušić, D., Krečak, I., Blaslov, V., Anđela, K. O., Valković, T., & Bašić‐Kinda, S. (2025) · Biomedicines · doi:10.3390/biomedicines13010207 · Cited by 1
Fan, L., & Zhao, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.29.888537 · Cited by 1
Evaluation of novel anti-tumoral strategies using peptide or monoclonal antibody immunotherapies
Mustapha, R. (2016) · theses.fr (ABES) · doi:10.70675/b62dded0z4f84z4e2cz86a9z0924d07b7877 · Cited by 1
Transcriptomic alterations of natural killer cells in multiple myeloma
Ekren, R. (2024) · theses.fr (ABES) · doi:10.70675/50e1dc40zb750z40fdzbaf3z80dca0320745 · Cited by 1
Crespo, A. V. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Elucidation of the cell signaling pathways mediating innate immunity and host-pathogen interactions
Nabar, N. R. (2019) · Figshare
Sequence matters: elotuzumab more effective if used before daratumumab
Pearse, R. N. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1703972
Zhang, P.-F., Zhang, M., Wu, Q., & Li, Q. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106444
RetractedDima, D., Hu, X., Dower, J., Zhang, D., Comenzo, R. L., & Varga, C. (2021) · Research Square · doi:10.21203/rs.3.rs-597058/v1
Monoklonális ellenanyag-alapú terápia myeloma multiplexben
Hardi, A., Kozma, A., Ceglédi, A., Tomán, Á., Bors, A., Andrikovics, H., & Mikala, G. (2021) · Hematológia–Transzfuziológia · doi:10.1556/2068.2021.54.1.5
Daratumumab for Immunoglobulin Light Chain Amyloidosis
Theodorakakou, F., Dimopoulos, M. A., & Kastritis, E. (2021) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2021.17.2.79
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_48-2
Antibody Therapies for Multiple Myeloma
Kanellias, N., Gavriatopoulou, M., & Terpos, E. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98656
Research progress in the role of CD38 in clinical tumor treatment.
He, Z., Liu, X., & Zhou, Y. (2022) · PubMed Central · doi:10.11817/j.issn.1672-7347.2022.210351
Zeynalova, P. A., Тимофеева, О. Л., Ryabukhina, Y. E., Abbasbeyli, F. M., Александровна, К. Н., Жуков, А. Г., & Valiev, T. T. (2023) · MD-Onco · doi:10.17650/2782-3202-2023-3-4-16-27
Ryabukhina, Y. E., Zeynalova, P. A., Abbasbeyli, F. M., Александровна, К. Н., Жуков, А. Г., Тимофеева, О. Л., & Valiev, T. T. (2024) · MD-Onco · doi:10.17650/2782-3202-2024-4-1-63-70
Hu, B., Wang, J., Fang, D., Jiang, L., Li, T., & Cao, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1619115
Light-chain-restricted hematogones are a potential diagnostic pitfall for B-cell lymphoma
Yang, X., Zhang, Z., & Yang, X. (2025) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_188_25
Mayer, K. A., Budde, K., Halloran, P. F., Doberer, K., Rostaing, L. P. E., Eskandary, F., Christamentl, A., Wahrmann, M., Regele, H. M., Schranz, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19556169
Huang, H., Zhu, J., Yao, M., Kim, T. M., Yoon, D. H., Cho, S.-G., Eom, H. S., Lim, S. T., Yeh, S.-P., Song, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14037298
Huang, H., Zhu, J., Yao, M., Kim, T. M., Yoon, D. H., Cho, S.-G., Eom, H. S., Lim, S. T., Yeh, S.-P., Song, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14037301
Mayer, K. A., Budde, K., Halloran, P. F., Doberer, K., Rostaing, L. P. E., Eskandary, F., Christamentl, A., Wahrmann, M., Regele, H. M., Schranz, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19556172
CD38-Inhibition als neuer Therapieansatz für die akute myeloische Leukämie
Farber, M. (2023) · DuEPublico (University of Duisburg-Essen) · doi:10.17185/duepublico/79006
Strategies to optimize natural killer cell functions in the tumor microenvironment
Susek, K. H. (2023) · Open Archive (Karolinska Institutet)
Giraldos Jimenez, D., Anel Bernal, L. A., & Naval Iraberri, J. J. (2023) · Zaguan (University of Zaragoza Repository)
Nuevas estrategias de inmunoterapia para el tratamiento del mieloma múltiple
Moreno-Narro, L. (., Panizo, C., & Paiva, B. (2020) · Depósito Académico Digital Universidad de Navarra (University of Navarra)
Baumann, N. (2023) · MACAU: Open Access Repository of Kiel University (University Library Kiel)
Mansour, R. A., Green, K. M., Graf, C., Chang, M., Magee, G., Davis, J. A., Zayad, A., Ahmed, N., Mushtaq, M. U., Ouchveridze, E., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70077
Jareckaitė, E. (2024) · Lithuanian University of Health Sciences
Giles, H. V. (2025) · University of Birmingham Institutional Research Archive (University of Birmingham)
Metadata
- Authors
- Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P.
- Affiliations
- Genmab (Netherlands) (NL)
- University Medical Center Utrecht (NL)
- Genmab , 3584 CM Utrecht,
- University of Southern Denmark (DK)
- Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center , 3584 CX Utrecht,
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-08-01
- Volume
- 197
- Issue
- 3
- Pages
- 807-813
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2443548094
- Cited by
- 297
- References
- 51
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 21 · 2023: 27 · 2022: 35 · 2021: 45 · 2020: 44 · 2019: 34 · 2018: 27 · 2017: 19 · 2016: 4
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- The Journal of Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- daratumumab, anti-CD38 monoclonal antibody, programmed cell death, multiple myeloma, FcRγ chain, FcγRIIB, FcγRIII, antibody-dependent cellular cytotoxicity
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Disease Models, Animal, Humans, Mice, Inbred C57BL, Multiple Myeloma, Tumor Cells, Cultured, Apoptosis, Receptors, IgG, Mice, Knockout, Mice, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.